Forte Biosciences (FBRX) Short-term Investments (2023 - 2024)
Forte Biosciences' (FBRX) quarterly Short-term Investments came in at $36.1 million in Q4 2024, up 261.68% on a QoQ basis from $10.0 million in Q2 2023.
Forte Biosciences (FBRX) Short-term Investments (2023 - 2024) Analysis & Trends
Forte Biosciences (FBRX) has 2 years of Short-term Investments data on file, last reported at $36.1 million in Q4 2024.
- On a quarterly basis, Short-term Investments changed N/A year-over-year to $36.1 million in Q4 2024; TTM through Dec 2024 was $36.1 million, a N/A change from a year earlier, with the FY2024 full-year figure at $36.1 million, changed N/A from the prior year.
- Short-term Investments for Q4 2024 stood at $36.1 million, up from $10.0 million in the prior quarter.
- Over the last five years, Short-term Investments for FBRX reached as high as $36.1 million in Q4 2024 and fell as low as $10.0 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Forte Biosciences | 174.08 Mn | 115.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 36.12 Mn |
| Jun 30, 2023 | 9.99 Mn |